Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Teva
Argus Health
Queensland Health
Accenture
Fish and Richardson

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,087,383

« Back to Dashboard

Which drugs does patent 6,087,383 protect, and when does it expire?

Patent 6,087,383 protects REYATAZ and EVOTAZ and is included in three NDAs.

Protection for REYATAZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in thirty-eight countries.

Summary for Patent: 6,087,383
Title: Bisulfate salt of HIV protease inhibitor
Abstract:The present invention provides the crystalline bisulfate salt of the formula ##STR1## which is found to have unexpectedly high solubility/dissolution rate and oral bioavailability relative to the free base form of this azapeptide HIV protease inhibitor compound.
Inventor(s): Singh; Janak (Lawrenceville, NJ), Pudipeddi; Madhusudhan (Plainsboro, NJ), Lindrud; Mark D. (Basking Ridge, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:09/217,538
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,087,383
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,087,383
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 6,087,383

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-001 Jun 20, 2003 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-002 Jun 20, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-003 Jun 20, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb REYATAZ atazanavir sulfate CAPSULE;ORAL 021567-004 Oct 16, 2006 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Julphar
Teva
Queensland Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.